Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019
October 11, 2019 16:05 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of...
Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer
October 01, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created...
Retrophin to Present at the 2019 Cantor Global Healthcare Conference
September 26, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare...
Retrophin Reports Second Quarter 2019 Financial Results
August 06, 2019 16:01 ET
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Commercial launch for THIOLA® EC underway following FDA-approval for the treatment of cystinuria Second quarter revenues...
Retrophin Reports First Quarter 2019 Financial Results
May 07, 2019 16:01 ET
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies FSGS and IgAN Continued...
Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
February 28, 2019 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS),...
Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results
February 12, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the...
Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
December 27, 2018 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial...